Challenges and progress in the development of a serogroup B meningococcal vaccine.
Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous effo...
| Autors principals: | , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2009
|